Predict your next investment

HEALTHCARE | Biotechnology
nightstarx.com

See what CB Insights has to offer

Founded Year

2013

Stage

Acq - P2P | Acquired

Total Raised

$100M

Valuation

$0000 

About Nightstar Therapeutics

Nightstar Therapeutics (NASDAQ: NITE) is a clinical-stage gene therapy company focused on developing and commercializing one-time treatments for patients suffering from rare inherited retinal diseases including choroideremia, X-linked retinitis pigmentosa and Best vitelliform macular dystrophy.

Nightstar Therapeutics Headquarter Location

215 Euston Road

London, England, NW1 2BE,

United Kingdom

+44-(0)20-7611-2031

Latest Nightstar Therapeutics News

Biogen’s ambitions in gene therapy hit by another failed pivotal trial

Jun 15, 2021

June 15, 2021 When Biogen acquired Nightstar Therapeutics in 2019, it added a pair inherited retinal disorder (IRD) gene therapies that it hoped would accelerate a push into the fast-evolving category. Just over two years later, both of those candidates have failed late-stage clinical trials, leaving Biogen’s $800 million investment in Nightstar looking like a poor deal. The latest to fail is timrepigene emparvovec, Nightstar’s lead IRD gene therapy candidate, which was unable to meet its primary or secondary treatment objectives in the phase 3 STAR study of patients with choroideraemia, a rare degenerative X-linked inherited retinal disorder that leads to blindness and has no approved treatments. The disappointing result comes just a few weeks after its X-linked retinitis pigmentosa (XLRP) candidate cotoretigene toliparvovec missed the mark in the phase 2/3 XIRIUS study. In STAR, the gene therapy was unable to achieve a significant improvement over baseline in the proportion of patients who had a 15 letter or better improvement in best corrected visual acuity (BCVA) as measured by an eye chart, its main endpoint. Biogen’s short announcement of the results also indicated that timrepigene emparvovec also fluffed the secondary endpoints in the trial, which included the change in BCVA from baseline a 10 letter or more improvement on the chart, and the percentage of patients with no decrease in eyesight over 12 months of follow-up. As with its announcement of the XLRP data, Biogen said it was waiting to evaluate the data from the trial fully before deciding on its future, but it seems likely that with a comprehensive failure across the board it will be discontinued. The company said it had seen positive trends on secondary measures in the XLRP study, but analysts have said that missing the main objective makes the programme look shaky given several other gene therapies for the disease are progressing through trials. Those include an Applied Genetic Technologies candidate which recently reported positive results in a phase 1/2 trial, MeiraGTx therapy – partnered with Johnson & Johnson – with phase 1/2 data in hand and phase 3 in preparation, and 4D Molecular Therapeutics therapy with a phase 1/2 readout due in the second half of this year. Biogen has made no secret of its aspirations in gene therapy, setting up a dedicated business unit for the category in 2014 and following that with a $1 billion alliance with Applied Genetic Technologies in 2015 – terminated three years later. Since buying Nightstar , it has also entered into a pair of platform technology deal with Capsigen and Ginkgo Bioworks, focused on engineering improved viral vectors for gene delivery. At the very least, the latest setback will divert attention briefly from the furore surrounding the FDA’s controversial approval of Biogen’s Alzheimer’s disease therapy Aduhelm (aducanumab) and the company’s decision to launch it with premium pricing despite limited efficacy data. Don't miss your daily pharmaphorum news.

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Research containing Nightstar Therapeutics

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Nightstar Therapeutics in 2 CB Insights research briefs, most recently on Mar 28, 2019.

Expert Collections containing Nightstar Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Nightstar Therapeutics is included in 2 Expert Collections, including Biopharmaceuticals.

B

Biopharmaceuticals

5,882 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

R

Regenerative Medicine

1,767 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).

Nightstar Therapeutics Patents

Nightstar Therapeutics has filed 1 patent.

The 3 most popular patent topics include:

  • Blindness
  • Diseases of the eye and adnexa
  • Disorders of choroid and retina
patents chart

Application Date

Grant Date

Title

Related Topics

Status

3/10/2016

Disorders of choroid and retina, Diseases of the eye and adnexa, Rare diseases, Visual system, Blindness

Application

Application Date

3/10/2016

Grant Date

Title

Related Topics

Disorders of choroid and retina, Diseases of the eye and adnexa, Rare diseases, Visual system, Blindness

Status

Application

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.